{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:31:23Z","timestamp":1772483483534,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.eururo.2014.12.004","type":"journal-article","created":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T23:16:40Z","timestamp":1419463000000},"page":"1039-1041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Observed Advantages of the STAMPEDE Study Design"],"prefix":"10.1016","volume":"67","author":[{"given":"Howard I.","family":"Scher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2014.12.004_bib0005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1745-6215-13-168","article-title":"Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial","volume":"13","author":"Sydes","year":"2012","journal-title":"Trials"},{"key":"10.1016\/j.eururo.2014.12.004_bib0010","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(12)70088-8","article-title":"Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial","volume":"13","author":"James","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2014.12.004_bib0075","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \u201cdocetaxel era\u201d: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08 CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.12.004_bib0020","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.12.004_bib0025","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.juro.2012.06.046","article-title":"Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346)","volume":"188","author":"Tangen","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.12.004_bib0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJM198908173210702","article-title":"A controlled trial of leuprolide with and without flutamide in prostatic carcinoma","volume":"321","author":"Crawford","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.12.004_bib0035","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","article-title":"Bilateral orchiectomy with or without flutamide for metastatic prostate cancer","volume":"339","author":"Eisenberger","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.12.004_bib0040","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","article-title":"Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916","volume":"27","author":"Hussain","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.12.004_bib0045","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.12.004_bib0050","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.12.004_bib0055","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.12.004_bib0060","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2011.34.6056","article-title":"Overall survival as the outcome for randomized clinical trials with effective subsequent therapies","volume":"29","author":"Korn","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.12.004_bib0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1470-2045(11)70295-9","article-title":"Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials","volume":"13","author":"D\u2019Amico","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2014.12.004_bib0070","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2014.05.038","article-title":"Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial","volume":"66","author":"Attard","year":"2014","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814012597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814012597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T14:26:53Z","timestamp":1537972013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283814012597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0302283814012597"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2014.12.004","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Observed Advantages of the STAMPEDE Study Design","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2014.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2014.09.032","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}